Key result
Long-term pharmacotherapy reduces LV volume by ~8 mL in HFrEF but shows no effect in HFpEF.
Why the study?
Does pharmacotherapy lead to long-term hemodynamic responses and reverse remodeling in HFpEF compared to HFrEF?
Meta-Analysis
Does pharmacotherapy lead to long-term hemodynamic responses and reverse remodeling in HFpEF compared to HFrEF?
Long-term pharmacotherapy induces clear reverse remodeling in HFrEF but not in HFpEF, despite having little effect on blood pressure and stroke volume augmentation in both conditions.
Answers are grounded in this paper and cite their sources.
Reinforces remodeling benefit of pharmacotherapy as HFrEF-specific; confirms divergent long-term responses across HF phenotypes.
, respectively). In HFrEF, treatment reduced LV end-diastolic and end-systolic volume (-8 and -6 mL, respectively), whereas in HFpEF there was no relevant change. Contrary to acute heart failure studies, long-term afterload reduction had little effect on blood pressure and stroke volume augmentation in both HFpEF and HFrEF. However, reverse remodeling was clearly present in HFrEF but was essentially absent in HFpEF.
No takes yet. Share an insight, caveat, or question.
Bovenkamp et al. (2025) conducted a meta-analysis in Heart failure with preserved and reduced ejection fraction (HFpEF and HFrEF). Pharmacotherapy was evaluated on LV end-diastolic and end-systolic volume. Long-term pharmacotherapy reduced LV end-diastolic and end-systolic volume in HFrEF, indicating reverse remodeling, whereas this effect was essentially absent in HFpEF.
Synapse has enriched 10 related papers. Consider them for comparative context: